Corundum Systems Biology

Corundum Systems Biology is an investment firm dedicated to advancing human health and well-being through systems biology solutions. The firm focuses on transformative breakthroughs by investing in disruptive ideas, foundational platforms, and early-stage ventures that convert complex scientific concepts into scalable, impact-driven solutions. Their mission is to shape the future of health by advancing the science of complexity, aiming for a world where human biology is decoded in real-time to enable predictive, preventative, and personalized health solutions at scale.

Established on April 30, 2020, Corundum Systems Biology was founded with a vision to accelerate human-centered discovery through the convergence of human-driven data, high-throughput technologies, and computational intelligence. The firm's approach emphasizes an integrated, dynamic understanding of biology, moving beyond traditional reductionist paradigms to capture the networks of interaction across genes, proteins, tissues, behaviors, species, and environments.

Corundum Systems Biology invests in scientific ventures with the potential to shift paradigms, backing technologies and teams that set new standards for precision, scalability, and clinical relevance. Their portfolio includes companies such as Sequential Bio, Holobiome, Freya Biosciences, ImYoo, and Axial Therapeutics, primarily focusing on the microbiome field and broader life sciences and healthtech sectors. The firm also engages in a Deep Phenotyping Platform to collect, organize, and analyze human multi-omics data, and provides research sponsoring to academic institutions like the Weizmann Institute of Science and Okinawa Institute of Science and Technology Graduate University.

The team at Corundum Systems Biology comprises scientists, strategists, builders, and investors with deep roots in academia, industry, and entrepreneurship. They operate as long-term partners and active contributors to their portfolio companies, bringing expertise across biology, data strategy, and venture building. Key team members include CEO Hidehiko Otake, Chief Scientific Officer Jessica Schneider, and Head of Data Strategy Rotem Gura Sadovsky, among others.